http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2578030-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_946fe725fd3395bfeb761c1a0dad36b7 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2014-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f09d912a28f61551ec829c1913321a01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad9666fc970f0beada95df2612759754 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_250a4033f913ca7917173e43c4c34bbc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73a1ef6fbac636229ab428160400e215 |
| publicationDate | 2016-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2578030-C2 |
| titleOfInvention | Method for prediction of reliability of response to routine two-component antiretroviral therapy with pegylated interferons and ribavirin in patients with chronic hepatitis c genotype 1b |
| abstract | FIELD: medicine. n SUBSTANCE: invention aims to predict a response to a routine two-component antiretroviral therapy in patients with chronic hepatitis C (CHC) genotype 1B. To predict the reliability of the response to the routine two-component antiretroviral therapy with pegylated interferons and ribavirin in patients with chronic hepatitis C genotype 1B, a genetic blood test is conducted to analyse IL28B gene polymorphism and specify a blood group. A stable virological response in 100% of the time is predicted in the patients with 0αβ (I) blood group and IL28B gene polymorphism rs12979860 in genotype C/C and rs8099917 in genotype T/T. A stable virological response in 80% of the time is predicted in the patients with Aβ (II) blood group and a one-nucleotide cytosine substitution by thymine (C>T) in rs12979860 locus of IL28B gene. If observing a one-nucleotide cytosine substitution by guanine (T>G) in rs8099917 of IL28B gene, the stable virological response is only predicted in the patients with Bα (III) blood group. n EFFECT: using invention enables the more reliable and effective prediction of the routine antiretroviral therapy. n 2 tbl |
| priorityDate | 2014-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.